Description
Ibrutix 140 MG (Ibrutinib) is an oral, first-generation covalent Bruton’s tyrosine kinase (BTK) inhibitor hard capsule available in a 140 mg strength, supplied in a pack of 120 capsules per pot, manufactured by Beacon Pharmaceuticals PLC of Bangladesh. The active ingredient, ibrutinib, is a highly selective, potent, irreversible BTK inhibitor that covalently binds to Cysteine-481 (Cys481) in the ATP-binding domain of Bruton’s tyrosine kinase (BTK), thereby permanently blocking B-cell receptor (BCR) signalling and downstream PI3K/AKT, NF-κB, and ERK/MAPK pro-survival cascades that sustain the proliferation, migration, and survival of malignant B-cells in chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), Waldenström’s macroglobulinaemia (WM), marginal zone lymphoma (MZL), and chronic graft-versus-host disease (cGVHD).
The reference-label starting dose of ibrutinib for CLL/SLL and Waldenström’s macroglobulinaemia is 420 mg once daily (QD), achieved with 3 × Ibrutix 140 MG capsules taken together once daily, with or without food, providing an approximately 40-day treatment supply from a single 120-capsule pot. For mantle cell lymphoma (MCL) and marginal zone lymphoma (MZL), the reference-label dose is 560 mg once daily (QD), achieved with 4 × Ibrutix 140 MG capsules once daily, providing a 30-day supply. In the pivotal Phase III RESONATE trial, ibrutinib delivered a progression-free survival (PFS) hazard ratio of 0.22 (95% CI 0.15–0.32; p<0.0001) versus ofatumumab in relapsed or refractory (R/R) CLL/SLL, with a 78% reduction in the risk of progression or death establishing ibrutinib as a cornerstone of modern B-cell malignancy treatment.
The overall response rate (ORR) in the RESONATE trial reached 42.6% with ibrutinib versus 4.1% with ofatumumab, with an additional 20% of ibrutinib-treated patients achieving partial response with lymphocytosis. In the first-line RESONATE-2 trial (treatment-naïve CLL patients ≥65 years), ibrutinib reduced the risk of progression or death by 84% versus chlorambucil (PFS HR 0.16; 95% CI 0.09–0.28; p<0.0001). Searching for Ibrutix 140 MG Ibrutinib? Mediaid Pharmacy stocks this product within its comprehensive oncology medicines portfolio and ships worldwide.
Basic Product Information of Ibrutix 140 MG (Ibrutinib)
| Brand Name | Ibrutix 140 MG (Ibrutinib) |
| Product Name | Ibrutix |
| Generic Name | Ibrutinib |
| Drug Class | First-Generation Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor; B-Cell Receptor (BCR) Signalling Pathway Inhibitor; Targeted Oncology Agent for B-Cell Malignancies (CLL, SLL, MCL, WM, MZL, cGVHD) |
| Formulation | Hard Capsule |
| Available Strength | 140 mg per capsule |
| Available Pack Size | 120 Capsules per pot (~40-day supply at the reference-label CLL/SLL/WM dose of 3 capsules/day [420 mg QD]; 30-day supply at the MCL/MZL dose of 4 capsules/day [560 mg QD]) |
| Primary Indications | Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL); Mantle Cell Lymphoma (MCL); Waldenström’s Macroglobulinaemia (WM); Marginal Zone Lymphoma (MZL); Chronic Graft-Versus-Host Disease (cGVHD) in Adult Patients |
| Reference-Label Starting Doses | CLL/SLL, WM, MZL, cGVHD: 420 mg QD = 3 × Ibrutix 140 MG capsules once daily | MCL: 560 mg QD = 4 × Ibrutix 140 MG capsules once daily; taken with or without food; swallowed whole with water |
| Manufacturer / Brand | Beacon Pharmaceuticals PLC, Bangladesh |
| Country of Origin | Bangladesh |
| Categories | Leukemia Medicines, Lymphoma Medicines, Oncology Medicines |
| Storage Conditions | Store below 25°C in a dry place, protected from light and moisture. Keep out of the reach of children. |
| Global Supplier | Mediaid Pharmacy Worldwide Shipping Available |
How Ibrutix 140 MG (Ibrutinib) Works: Irreversible Covalent BTK Inhibition and B-Cell Receptor Signalling Blockade in B-Cell Malignancies
Ibrutinib, the active ingredient in Ibrutix 140 MG, is an orally bioavailable, first-in-class, covalent Bruton’s tyrosine kinase (BTK) inhibitor that irreversibly suppresses BTK the central kinase mediating B-cell receptor (BCR) signalling by forming a permanent covalent bond with Cysteine-481 (Cys481) in the BTK ATP-binding domain. This covalent bond completely and irreversibly inactivates BTK enzymatic activity, thereby abolishing BCR-driven downstream signalling through the PI3K/AKT, NF-κB, and ERK/MAPK pathways that sustain malignant B-cell proliferation, survival, homing, and retention in lymphoid tissues and the bone marrow microenvironment.
A covalent BTK inhibitor refers to a small molecule that binds BTK through an irreversible covalent interaction specifically via Michael addition to Cys481 in contrast to reversible kinase inhibitors, ensuring that BTK suppression persists until new BTK protein is synthesised, conferring a pharmacodynamically durable inhibition independent of plasma drug concentration fluctuations. Ibrutinib’s IC₅₀ for BTK is approximately 0.5 nM, confirming subnanomolar potency at its primary target. Each Ibrutix 140 MG hard capsule contains ibrutinib equivalent to 140 mg, with the standard CLL/SLL and WM reference-label dose of 420 mg QD delivered by taking 3 capsules once daily, with or without food.
BCR signalling pathway dependence is the central oncogenic vulnerability exploited by ibrutinib: in CLL, MCL, WM, and MZL, constitutive or tonically active BCR signalling drives malignant B-cell survival through NF-κB-mediated transcription of pro-survival genes (BCL-2, MCL-1, BFL-1) and PI3K/AKT-mediated inhibition of apoptosis. Ibrutinib’s irreversible BTK blockade severs this signalling axis completely, inducing caspase-dependent apoptosis and inhibiting cell-cycle progression in BTK-dependent B-cell tumours. CXCR4/CXCL12 and VLA-4 integrin signalling, which mediate malignant B-cell retention and homing in the bone marrow and lymph node microenvironment, are also disrupted by BTK inhibition, mobilising CLL cells from protective niches into the peripheral circulation the mechanistic basis of the transient lymphocytosis observed in patients initiating ibrutinib therapy.
Additional kinase inhibition by ibrutinib at clinically relevant concentrations includes ITK (interleukin-2-inducible T-cell kinase), HER2/ErbB2, BLK, TEC, and TXK the off-target ITK inhibition contributes to ibrutinib’s immunomodulatory effects on the tumour microenvironment and has been associated with the characteristic ibrutinib-related bleeding and atrial fibrillation risk. In the pivotal Phase III RESONATE trial 391 patients with previously treated CLL/SLL ibrutinib at 420 mg QD (achievable as 3 × Ibrutix 140 MG capsules once daily) delivered a PFS HR of 0.22 (95% CI 0.15–0.32; p<0.0001) versus ofatumumab. Oncologists managing patients with B-cell leukaemia can review the full range of leukemia medicines at Mediaid Pharmacy, including Ibrutix 140 MG Ibrutinib, for comprehensive B-cell malignancy treatment programme planning.
In the RESONATE trial, the ORR was 42.6% with ibrutinib versus 4.1% with ofatumumab; with partial responses with lymphocytosis included, the total response rate reached 62.7% for ibrutinib. The 12-month PFS rate was 88% for ibrutinib versus 65% for ofatumumab. In the first-line RESONATE-2 trial (treatment-naïve CLL patients aged ≥65 years), ibrutinib versus chlorambucil delivered a PFS HR of 0.16 (95% CI 0.09–0.28; p<0.0001), with a 5-year PFS rate of 70% for ibrutinib versus 12% for chlorambucil confirming ibrutinib’s sustained clinical benefit across both relapsed/refractory and treatment-naïve CLL. The ibrutinib dose for each patient must be determined and adjusted by the treating haematologist or oncologist; Ibrutix 140 MG capsules must be prescribed and taken under the supervision of a qualified haematology-oncology specialist.
Approved Indications of Ibrutinib Ibrutix 140 MG Reference Label
Ibrutinib is approved in numerous countries for the treatment of multiple B-cell malignancies. The 140 mg hard capsule formulation of Ibrutix, with its 120-capsule pack size, supports the reference-label doses across all approved indications without requiring supplementary capsule strengths. Prescribers must confirm the exact locally approved indication on the ibrutinib product label before initiating therapy, as specific label language varies by regulatory jurisdiction. The prescribing oncologist must also confirm mutation status where applicable (e.g., del(17p), TP53 mutation in CLL) to guide treatment sequencing.
|
Chronic Lymphocytic Leukaemia (CLL) / Small Lymphocytic Lymphoma (SLL) Adult Patients Ibrutinib is indicated as monotherapy or in combination with rituximab, obinutuzumab, or venetoclax for the treatment of adult patients with CLL/SLL, including patients with del(17p) or TP53 mutation, as first-line or relapsed/refractory therapy. Reference-label dose: 420 mg once daily (QD) = 3 × Ibrutix 140 MG capsules per day, taken together with or without food. The RESONATE Phase III trial confirmed PFS HR 0.22 (p<0.0001) versus ofatumumab in R/R CLL; RESONATE-2 confirmed PFS HR 0.16 (p<0.0001) versus chlorambucil in treatment-naïve CLL. Oncologists can review the full range of leukaemia targeted therapy medicines at Mediaid Pharmacy alongside Ibrutix for comprehensive CLL/SLL programme planning. |
Mantle Cell Lymphoma (MCL) Adult Patients After at Least One Prior Therapy Ibrutinib is indicated for adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, as well as in certain first-line MCL settings in combination. Reference-label dose: 560 mg once daily (QD) = 4 × Ibrutix 140 MG capsules per day. The pivotal Phase II MCL study demonstrated an ORR of 68% (CR 21%, PR 47%) with a median duration of response of 17.5 months in heavily pretreated R/R MCL patients. The 120-capsule pot of Ibrutix 140 MG provides a full 30-day supply at the 560 mg QD MCL dose. Oncologists managing MCL patients can also review lymphoma medicines at Mediaid Pharmacy for comprehensive programme support. |
|
Waldenström’s Macroglobulinaemia (WM) Adult Patients Ibrutinib is indicated for adult patients with Waldenström’s macroglobulinaemia (WM) as monotherapy or in combination with rituximab, for previously treated patients or first-line patients for whom chemoimmunotherapy is not appropriate. Reference-label dose: 420 mg once daily (QD) = 3 × Ibrutix 140 MG capsules per day. In a Phase III trial of ibrutinib + rituximab versus placebo + rituximab in WM, the 30-month PFS was 82% versus 28% (HR 0.20; p<0.0001), with ORR 92% versus 47%. MYD88 L265P mutation status informs expected depth of response; CXCR4 mutation may predict attenuated response kinetics. |
Marginal Zone Lymphoma (MZL) and Chronic Graft-Versus-Host Disease (cGVHD) Adult Patients Ibrutinib is indicated for adult patients with previously treated marginal zone lymphoma (MZL) at 560 mg QD (4 × Ibrutix 140 MG capsules), and for adult patients with chronic graft-versus-host disease (cGVHD) who have failed one or more lines of systemic therapy at 420 mg QD (3 × Ibrutix 140 MG capsules). In the pivotal cGVHD trial, the ORR was 67% (complete response 21%) in patients with heavily pretreated, corticosteroid-dependent cGVHD, establishing ibrutinib as the first BTK inhibitor approved for this post-transplant complication. Prescribers must confirm the locally approved label for each indication before initiating Ibrutix 140 MG therapy. |
Ibrutix 140 MG (Ibrutinib) Dosing: Reference-Label Dose Schedule and Modification Algorithm by Indication
The reference-label ibrutinib doses across approved indications are achievable using multiples of the Ibrutix 140 MG hard capsule without requiring other tablet strengths, making Ibrutix 140 MG a clinically aligned and operationally flexible generic ibrutinib option. All doses are administered orally, once daily, at approximately the same time each day, with or without food. Capsules must be swallowed whole with water and must not be opened, crushed, or chewed.
| Indication | Ibrutinib Dose (mg QD) | Ibrutix 140 MG Capsules Per Day | Days Supply from 120-Capsule Pot |
| CLL / SLL (1st line and R/R) | 420 mg QD | 3 capsules once daily | ~40 days |
| MCL (R/R; ≥1 prior therapy) | 560 mg QD | 4 capsules once daily | 30 days |
| Waldenström’s Macroglobulinaemia (WM) | 420 mg QD | 3 capsules once daily | ~40 days |
| Marginal Zone Lymphoma (MZL) | 560 mg QD | 4 capsules once daily | 30 days |
| Chronic Graft-Versus-Host Disease (cGVHD) | 420 mg QD | 3 capsules once daily | ~40 days |
| Dose Reduction Step 1 (for toxicity) | 420 mg → 280 mg QD (CLL); 560 mg → 420 mg QD (MCL/MZL) | 2 capsules once daily | 60 days |
| Dose Reduction Step 2 (for persistent toxicity) | 140 mg QD | 1 capsule once daily | 120 days |
Safety Monitoring Requirements for Ibrutix 140 MG (Ibrutinib) Therapy
Cardiovascular monitoring is a critical safety requirement throughout ibrutinib therapy. Atrial fibrillation (AF) and atrial flutter are reported in approximately 6–16% of ibrutinib-treated patients across indications, with incidence increasing with age and duration of therapy. All patients must undergo baseline ECG and cardiovascular assessment before initiating Ibrutix 140 MG therapy; any new palpitations, dyspnoea, or presyncope during treatment must be evaluated with urgent ECG. Ibrutinib should be interrupted for new-onset AF or atrial flutter and may be resumed at the same or reduced dose after specialist cardiology review; if AF recurs or is not manageable, permanent discontinuation is required. Hypertension develops in approximately 14–29% of patients receiving ibrutinib long-term and must be monitored at baseline and throughout treatment, with antihypertensive therapy initiated as clinically indicated.
Bleeding and haemorrhagic event monitoring: ibrutinib inhibits collagen-induced platelet aggregation through off-target ITK and TEC inhibition, conferring an antiplatelet effect independent of the platelet count. Grade 3 or higher haemorrhagic events including subdural haematoma, gastrointestinal bleeding, and haematuria are reported in approximately 1–6% of ibrutinib-treated patients. Patients must be counselled on bruising and bleeding signs at initiation; ibrutinib must be interrupted for at least 3–7 days before and after elective surgical procedures. Concurrent use of anticoagulants (warfarin, DOACs) and antiplatelet agents with ibrutinib substantially amplifies haemorrhagic risk and requires individualised benefit–risk assessment and increased monitoring by the treating oncologist.
Infection risk monitoring: ibrutinib-treated patients carry elevated susceptibility to bacterial, viral, and opportunistic fungal infections, including Pneumocystis jirovecii pneumonia (PJP) and invasive aspergillosis in heavily immunosuppressed patients. Complete blood count (CBC) with differential at baseline and periodically throughout treatment is mandatory to detect treatment-emergent cytopenias (neutropenia, thrombocytopenia) that amplify infection risk. Opportunistic infection prophylaxis should be considered in high-risk patients per institutional guidelines. Hepatic function monitoring: liver enzyme elevations occur in some ibrutinib-treated patients; LFT monitoring at baseline and during treatment is recommended. Tumour lysis syndrome (TLS): patients with high tumour burden particularly in CLL are at risk of TLS at initiation; hydration and uric acid monitoring are required in high-risk patients. Oncologists managing patients on ibrutinib who also require supportive or combination agents can review the full selection of oncology medicines at Mediaid Pharmacy for comprehensive programme support.
Drug Interactions and Important Safety Information for Ibrutix 140 MG (Ibrutinib)
The most clinically significant pharmacokinetic drug interaction risk for ibrutinib involves CYP3A4 modulators and P-glycoprotein (P-gp) inhibitors. Ibrutinib is primarily metabolised by CYP3A4 and is also a P-gp substrate. Strong CYP3A4 inducers including rifampicin, carbamazepine, phenytoin, phenobarbital, and St. John’s Wort (Hypericum perforatum) markedly increase ibrutinib metabolism and reduce systemic exposure, potentially compromising antitumour efficacy; clinical pharmacology data indicate rifampicin reduces ibrutinib AUC by approximately 90%. Avoidance of strong CYP3A4 inducers is mandatory where clinically feasible; if unavoidable, dose escalation under oncologist supervision and additional monitoring are required.
Strong CYP3A4 inhibitors including ketoconazole, itraconazole, voriconazole, posaconazole, fluconazole, clarithromycin, and ritonavir-boosted HIV medications may substantially increase ibrutinib systemic exposure (up to 24-fold with posaconazole) and amplify toxicity risk including haemorrhage, AF, and myelosuppression. Where strong azole antifungals required for prophylaxis or treatment of fungal infections in immunocompromised haematology patients cannot be avoided, ibrutinib dose interruption or reduction to 140 mg QD (1 × Ibrutix 140 MG capsule) must be considered under oncologist supervision. Moderate CYP3A4 inhibitors including diltiazem, erythromycin, fluconazole, and grapefruit juice require dose modification to 280 mg QD (2 × Ibrutix 140 MG capsules) with increased clinical vigilance.
Anticoagulant and antiplatelet interactions: ibrutinib’s intrinsic platelet-inhibitory effect (via ITK/TEC off-target inhibition) is substantially amplified by concomitant anticoagulants (warfarin, DOACs: apixaban, rivaroxaban, dabigatran) and antiplatelet agents (aspirin, clopidogrel). Warfarin is contraindicated by the ibrutinib reference label; DOACs require individualised benefit–risk assessment and increased haemorrhagic monitoring. P-gp inhibitors including certain antifungals and HIV antiretrovirals may increase ibrutinib plasma concentrations and require clinical monitoring and dose adjustment.
QT interval-prolonging agents: ibrutinib itself is associated with AF risk; concurrent use of QTc-prolonging medications including antiarrhythmics (amiodarone, sotalol), fluoroquinolones (moxifloxacin, ciprofloxacin), macrolides (azithromycin, clarithromycin), and antipsychotics amplifies cardiac arrhythmia risk and requires ECG monitoring. Venetoclax combination: when ibrutinib is combined with venetoclax (an approved combination for CLL/SLL), tumour lysis syndrome risk is amplified and mandatory TLS prophylaxis protocols dose ramp-up, hydration, uric acid monitoring must be followed per the treating oncologist’s protocol. Patients must disclose all concomitant medications, supplements, herbal preparations, and over-the-counter agents to their treating haematologist-oncologist before and during Ibrutix 140 MG therapy. Teams requiring concurrent oncology agents alongside ibrutinib-based leukaemia regimens at Mediaid Pharmacy can contact the team for multi-medicine sourcing support.
Side Effects and Precautions of Ibrutix 140 MG (Ibrutinib)
|
Common Side Effects Diarrhoea (approximately 43%); the most frequently reported gastrointestinal adverse event; typically mild to moderate (Grade 1–2) and manageable with antidiarrhoeal agents, hydration, and dietary modification; Grade 3 events in approximately 3–5% of patients Fatigue and asthenia (approximately 40%); often multifactorial, contributed to by disease burden, concurrent cytopenias, and direct drug-related effects; typically improves over the first 3–6 months of continuous therapy Musculoskeletal pain including arthralgia and myalgia (approximately 30–37%); a distinctive ibrutinib-associated adverse event particularly prominent in the first months of therapy; typically managed with analgesics and dose modification when Grade 3 or higher Nausea (approximately 28%); peripheral oedema (approximately 35%); rash and dermatological reactions (approximately 25–27%); upper respiratory tract infection (approximately 34%); bruising and contusion (approximately 19–30%) Neutropenia (approximately 19–26%); thrombocytopenia (approximately 17–23%); anaemia (approximately 12–17%); CBC monitoring at baseline and throughout treatment is mandatory Atrial fibrillation (approximately 6–16%); hypertension (approximately 14–29%); dizziness (approximately 11%); headache (approximately 13%); stomatitis (approximately 17%) |
Serious Warnings and Precautions Major haemorrhage including fatal events: Grade 3 or higher haemorrhagic events reported in approximately 1–6% of ibrutinib-treated patients, including subdural haematoma, gastrointestinal haemorrhage, and haemoptysis. Ibrutinib must be interrupted for at least 3–7 days before and after any elective surgery. Anticoagulant and antiplatelet combinations require individualised benefit–risk assessment and intensified monitoring. Atrial fibrillation and atrial flutter: reported in approximately 6–16% of patients; incidence increases with age and treatment duration. Mandatory baseline and periodic ECG monitoring. Ibrutinib must be interrupted for new-onset AF and may require permanent discontinuation if arrhythmia recurs or is unmanageable. Cardiology consultation is required before restarting ibrutinib after an AF event. Serious and opportunistic infections: bacterial, viral (including reactivation of hepatitis B and herpes zoster), and fungal infections reported with ibrutinib therapy. Hepatitis B virus (HBV) status must be established before initiating ibrutinib; patients with HBsAg positivity require prophylactic antiviral therapy. PJP prophylaxis should be considered in high-risk or heavily pre-treated patients. Hypertension requiring antihypertensive intervention develops in approximately 14–29% of patients on long-term ibrutinib; blood pressure monitoring at baseline and regular intervals throughout therapy is mandatory. Grade 3 hypertension requiring urgent antihypertensive intervention has been reported. Second primary malignancies including non-melanoma skin cancers have been reported with ibrutinib therapy; annual dermatological review is recommended. Tumour lysis syndrome (TLS) requires monitoring and prophylaxis in high-tumour-burden patients, particularly at CLL therapy initiation. Embryo-fetal toxicity: ibrutinib can cause fetal harm based on its mechanism of action and animal reproductive toxicology data. Females of reproductive potential must use effective contraception during treatment and for 1 month after the final dose. Males with female partners of reproductive potential must use contraception during treatment and for 1 month after the final dose. Breastfeeding is contraindicated during treatment and for 2 months after the final dose. |
Who Should Use Ibrutix 140 MG (Ibrutinib)?
Ibrutix 140 MG (Ibrutinib) is indicated for adult patients with the following B-cell malignancies: chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) in the first-line or relapsed/refractory setting, including patients with high-risk cytogenetics such as del(17p) or TP53 mutation; mantle cell lymphoma (MCL) after at least one prior therapy; Waldenström’s macroglobulinaemia (WM) with or without rituximab; previously treated marginal zone lymphoma (MZL); and chronic graft-versus-host disease (cGVHD) after failure of one or more systemic therapy lines. The 140 mg hard capsule formulation with a 120-capsule pot is clinically appropriate for any adult patient requiring any of the reference-label ibrutinib doses across all approved indications 420 mg QD (3 capsules), 560 mg QD (4 capsules), or dose reductions to 280 mg QD (2 capsules) or 140 mg QD (1 capsule) covering the complete reference-label dose modification pathway without supplementary capsule strengths.
Haematologists and oncologists must assess baseline cardiovascular status (ECG, blood pressure), complete blood count (CBC), hepatic function (ALT, AST, bilirubin), renal function, HBV serology (HBsAg, anti-HBc), bleeding history, and all concomitant medications particularly CYP3A4 inhibitors/inducers, anticoagulants, antiplatelet agents, and QTc-prolonging drugs before prescribing any ibrutinib dose. Patients with pre-existing AF, significant cardiovascular disease, or active bleeding disorders require specialist cardiology assessment before initiation. Oncologists seeking comprehensive targeted agent support across leukaemia and B-cell lymphoma treatment programmes can review the full range of lymphoma medicines at Mediaid Pharmacy, including Ibrutix 140 MG Ibrutinib for CLL, MCL, WM, and MZL after prior therapy.
Global Supplier: Mediaid Pharmacy Worldwide Shipping for Ibrutix 140 MG (Ibrutinib)
Mediaid Pharmacy is a Dhaka-based supplier of oncology and specialty medicines with worldwide shipping capacity. Ibrutix 140 MG (Ibrutinib) manufactured by Beacon Pharmaceuticals PLC of Bangladesh, formulated as hard capsules in 120-capsule pots, is stocked and available for international supply. All orders are supported by pricing quotations, stock confirmation, and end-to-end delivery tracking. Hospitals, specialist haematology and oncology clinics, cancer centres, CLL and lymphoma treatment programmes, distributors, and patients in countries where ibrutinib is approved can contact the Mediaid Pharmacy team through WhatsApp, phone, or WeChat for all enquiries about oral ibrutinib capsules for CLL, SLL, MCL, and WM at Mediaid Pharmacy, including current stock availability, pricing, and international delivery timelines. Institutions and distributors sourcing multiple oncology medicines in a single consolidated shipment can request a combined quotation from the Mediaid Pharmacy team after browsing the full catalogue.
Why Choose Ibrutix 140 MG (Ibrutinib) from Mediaid Pharmacy?
Ibrutix 140 MG is manufactured by Beacon Pharmaceuticals PLC of Bangladesh and delivers ibrutinib the first-in-class covalent BTK inhibitor whose 420 mg QD dose anchored the RESONATE Phase III trial (PFS HR 0.22; p<0.0001; ORR 42.6% vs 4.1% versus ofatumumab in R/R CLL) and whose 420 mg QD first-line data from RESONATE-2 established an 84% reduction in PFS risk versus chlorambucil in treatment-naïve CLL (PFS HR 0.16; 95% CI 0.09–0.28; p<0.0001; 5-year PFS 70% vs 12%). The defining procurement advantage of sourcing Ibrutix 140 MG from Mediaid Pharmacy is complete reference-label dosing coverage from a single generic ibrutinib capsule supplier: the 140 mg capsule enables the full CLL/SLL/WM/cGVHD starting dose of 420 mg QD (3 capsules once daily), the MCL/MZL starting dose of 560 mg QD (4 capsules once daily), the first dose reduction to 280 mg QD (2 capsules once daily), and the second dose reduction to 140 mg QD (1 capsule once daily) covering the complete reference-label dose modification pathway without the need for supplementary capsule strengths.
Mediaid Pharmacy supplies Ibrutix 140 MG in its 120-capsule pot format with worldwide shipping, specialist supply support, and documentation for customs clearance as required. Every order is initiated with a prescription-based enquiry to maintain supply aligned with the treating oncologist’s clinical plan. For oncology programmes requiring a broader panel of targeted and supportive agents, the full Mediaid Pharmacy oncology medicines catalogue is available to browse, and the team can be contacted directly for consolidated multi-medicine quotations.
Frequently Asked Questions About Ibrutix 140 MG (Ibrutinib)
What is Ibrutix 140 MG and what is its generic name?
Ibrutix 140 MG is a branded generic ibrutinib hard capsule manufactured by Beacon Pharmaceuticals PLC of Bangladesh. The generic name of Ibrutix 140 MG is ibrutinib the same active ingredient as the originator medicine Imbruvica (ibrutinib), originally developed by Pharmacyclics and Janssen Biotech and first approved by the FDA in November 2013 (for MCL), with subsequent approvals for CLL, WM, MZL, and cGVHD by the FDA, EMA, and other major regulatory agencies globally. Each Ibrutix 140 MG hard capsule contains ibrutinib equivalent to 140 mg. The 120-capsule pot of Ibrutix 140 MG provides an approximately 40-day supply at the reference-label CLL/SLL/WM/cGVHD starting dose of 420 mg QD (3 capsules per day) and a 30-day supply at the MCL/MZL reference-label dose of 560 mg QD (4 capsules per day), making Ibrutix 140 MG a clinically aligned, cost-accessible generic ibrutinib option for haematology-oncology programmes treating B-cell malignancy patients worldwide.
How should Ibrutix 140 MG (Ibrutinib) capsules be taken?
Ibrutix 140 MG (Ibrutinib) capsules are taken orally at the dose and schedule prescribed by the treating haematologist or oncologist. The reference-label dose for CLL/SLL, WM, and cGVHD is 420 mg once daily (3 × Ibrutix 140 MG capsules taken together once daily); the reference-label dose for MCL and MZL is 560 mg once daily (4 × Ibrutix 140 MG capsules once daily). Unlike many oral targeted agents with strict food-effect requirements, ibrutinib can be taken with or without food; however, patients should be consistent in administration timing relative to meals and avoid grapefruit juice and Seville oranges (which contain moderate CYP3A4 inhibitors) throughout therapy. Capsules must be swallowed whole with a glass of water and must not be opened, crushed, chewed, or dissolved, as altering the capsule would change ibrutinib absorption. If a dose is missed and it is still on the same day, the missed dose should be taken as soon as remembered on that day. If the missed dose is not remembered until the next day, the missed dose must be skipped and the regular dosing schedule resumed patients must never take two doses on the same day to compensate for a missed dose. Patients must inform their treating oncologist immediately about any new concomitant medications particularly azole antifungals, antiretrovirals, anticoagulants, or antiplatelet agents that could interact with ibrutinib.
What are the most common side effects of Ibrutix 140 MG (Ibrutinib)?
The most common side effects of ibrutinib across Phase III trials and all approved indications include diarrhoea (approximately 43%), fatigue and asthenia (approximately 40%), musculoskeletal pain including arthralgia and myalgia (approximately 30–37%), upper respiratory tract infection (approximately 34%), peripheral oedema (approximately 35%), nausea (approximately 28%), rash and dermatological reactions (approximately 25–27%), bruising and contusion (approximately 19–30%), stomatitis (approximately 17%), dizziness (approximately 11%), and headache (approximately 13%). Atrial fibrillation and atrial flutter are distinctive and clinically critical adverse events reported in approximately 6–16% of ibrutinib-treated patients, with incidence increasing with age and treatment duration, requiring mandatory cardiac monitoring throughout therapy. Hypertension develops in approximately 14–29% of patients on long-term ibrutinib. Grade 3 or higher haemorrhagic events including major bleeding are reported in approximately 1–6% of patients. The reference-label dose modification algorithm permits stepwise reductions from 420 mg QD to 280 mg QD and then to 140 mg QD using Ibrutix 140 MG capsules. Consult your prescribing haematologist-oncologist regarding your individual risk profile before and during treatment.
What is the evidence base for ibrutinib in CLL/SLL?
The pivotal evidence for ibrutinib in CLL/SLL is derived from two Phase III trials. The RESONATE trial (NCT01578707) enrolled 391 patients with previously treated CLL/SLL and randomised them 1:1 to ibrutinib 420 mg QD versus ofatumumab; the primary endpoint of PFS was met with high statistical significance: PFS HR 0.22 (95% CI 0.15–0.32; p<0.0001), with the 12-month PFS rate of 88% for ibrutinib versus 65% for ofatumumab, and ORR of 42.6% versus 4.1%. The RESONATE-2 trial (NCT01722487) enrolled 269 treatment-naïve CLL patients aged ≥65 years and randomised them to ibrutinib 420 mg QD versus chlorambucil; the primary endpoint of PFS delivered HR 0.16 (95% CI 0.09–0.28; p<0.0001) in favour of ibrutinib, with a 5-year PFS rate of 70% versus 12% and a 5-year OS rate of 83% versus 68%. The PFS benefit of ibrutinib was consistent across all patient subgroups in both trials, including patients with del(17p) or TP53 mutation the highest-risk cytogenetic subgroup in CLL where ibrutinib demonstrates preserved efficacy that is not achievable with standard chemoimmunotherapy. Ibrutix 140 MG delivers ibrutinib at the RESONATE and RESONATE-2 reference dose of 420 mg QD, with 3 capsules once daily from a 120-capsule pot providing an approximately 40-day treatment supply.
Is Ibrutix 140 MG (Ibrutinib) safe during pregnancy or while breastfeeding?
No. Ibrutinib including in the Ibrutix 140 MG hard capsule formulation can cause fetal harm based on its mechanism of action (BTK inhibition suppresses signalling pathways essential for normal fetal B-cell development, foetal vascular development, and haematopoiesis) and confirmed animal reproductive toxicology data, which demonstrated embryotoxicity, fetotoxicity, and teratogenicity in multiple species at exposures within or below the human therapeutic range. Females of reproductive potential must use effective non-hormonal contraception during treatment with Ibrutix 140 MG and for at least 1 month after the final dose. Males with female partners of reproductive potential must also use effective contraception during treatment and for at least 1 month after the final dose. Breastfeeding is not recommended during treatment and for at least 2 months after the final dose, as it has not been established whether ibrutinib or its active metabolite PCI-45227 are excreted in human breast milk. Patients who are pregnant, planning a pregnancy, or breastfeeding must discuss their individual circumstances with their treating haematologist-oncologist before initiating ibrutinib therapy.
What makes ibrutinib different from second-generation BTK inhibitors like acalabrutinib or zanubrutinib?
Ibrutinib is the first-generation, first-in-class covalent BTK inhibitor that established BTK as a validated therapeutic target in B-cell malignancies and demonstrated OS benefit in multiple large Phase III trials across CLL, MCL, and WM. Second-generation covalent BTK inhibitors acalabrutinib (Calquence) and zanubrutinib (Brukinsa) were developed to improve upon ibrutinib’s selectivity profile by reducing off-target kinase inhibition (particularly ITK, TEC, HER2, and TXK inhibition) that contributes to ibrutinib’s atrial fibrillation, bleeding, and musculoskeletal pain adverse event profile. In head-to-head Phase III comparisons: (1) ELEVATE-RR demonstrated that acalabrutinib was non-inferior to ibrutinib for PFS in high-risk R/R CLL with a significantly lower rate of AF (9.4% vs 16.0%; p=0.02) and major haemorrhage; (2) ALPINE demonstrated that zanubrutinib was superior to ibrutinib for PFS in R/R CLL (PFS HR 0.65; p=0.002) with significantly lower AF rates (5.2% vs 10.1%). However, ibrutinib retains the most extensive long-term efficacy and safety data across the broadest indication portfolio, remains the only BTK inhibitor approved for cGVHD in many jurisdictions, and is available as a cost-accessible generic formulation through Ibrutix 140 MG for treatment programmes where ibrutinib remains the most appropriate or accessible BTK inhibitor choice.
Can I order Ibrutix 140 MG (Ibrutinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Ibrutix 140 MG (Ibrutinib) manufactured by Beacon Pharmaceuticals PLC of Bangladesh hard capsules, 120 capsules per pot to oncology centres, hospitals, distributors, and patients globally. Contact Mediaid Pharmacy via WhatsApp, phone, or WeChat at +8801773428128, or email info@mediaidpharmacy.com, for pricing on Ibrutix 140 MG Ibrutinib, current stock availability, and international delivery details for your country. Oncology teams sourcing Ibrutix 140 MG Ibrutinib alongside other targeted agents for leukaemia and lymphoma programmes can browse the complete range of oncology medicines at Mediaid Pharmacy and request a consolidated multi-medicine quotation. All orders are supported by prescription verification, pricing documentation, and customs clearance support as required for international shipments.
Order Ibrutix 140 MG (Ibrutinib) with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com




Reviews
There are no reviews yet.